Taysha Gene Therapies/$TSHA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Taysha Gene Therapies

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Ticker

$TSHA
Sector
Primary listing

Employees

73

TSHA Metrics

BasicAdvanced
$889M
-
-$0.34
0.96
-

What the Analysts think about TSHA

Analyst ratings (Buy, Hold, Sell) for Taysha Gene Therapies stock.

Bulls say / Bears say

Taysha has obtained written agreement from the FDA on the design of the pivotal Part B REVEAL trial and can submit the trial protocol and statistical plan as an IND amendment—potentially accelerating study start and registration by skipping a formal end-of-phase meeting.
Both high and low doses of TSHA-102 have shown a positive safety profile so far, with no treatment-related serious adverse events or dose-limiting toxicities in pediatric, adolescent, and adult participants across REVEAL Phase 1/2 trials.
Results from REVEAL Part A demonstrated a 100% responder rate for the primary endpoint—gaining or regaining at least one developmental milestone—supporting TSHA-102’s potential therapeutic benefit in treating Rett syndrome.
Taysha’s entire pipeline depends on a single clinical-stage asset, TSHA-102. If this program fails or is delayed, the company’s business would be significantly affected since there are no alternative late-stage candidates.
Efficacy and safety results are drawn from a very small cohort of 10 patients in REVEAL Part A, so these preliminary findings have a high risk of failure or may not be reproducible in larger pivotal trials.
Gene therapy development for the central nervous system (CNS) is typically very costly and time-consuming. Taysha may need significant additional funding, raising the risk of shareholder dilution if clinical or regulatory milestones are delayed beyond its current cash reserves.
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.

TSHA Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TSHA Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TSHA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs